Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing

Area of Science:

• Hepatology and Toxicology
• Stem Cell Biology
• Drug Development and Safety

Background:

• Drug-induced liver injury (DILI) is a major cause of drug development failure.
• Current hepatocyte models (primary human hepatocytes, animal models, cell lines) have limitations including species differences and difficult extraction.
• There is a critical need for novel, cost-effective, and accurate drug screening models.

Purpose of the Study:

• To review stem cell sources for generating hepatocyte-like cells.
• To discuss hepatotoxicity testing models utilizing stem cell-derived hepatocytes.
• To highlight the potential of stem cells in improving drug safety assessment.

Main Methods:

• Review of literature on stem cell sources (e.g., pluripotent stem cells, adult stem cells).
• Analysis of 3D culture techniques for mimicking in vivo microenvironments.
• Evaluation of stem cell-derived hepatocyte models for drug screening applications.

Main Results:

• Stem cells provide a renewable and abundant source for generating functional hepatocyte-like cells.
• 3D culture systems enhance the accuracy of stem cell-derived hepatocyte models compared to 2D cultures.
• These models show potential for more reliable prediction of drug-induced hepatotoxicity.

Conclusions:

• Stem cell-derived hepatocytes, particularly in 3D cultures, represent a significant advancement in DILI screening.
• These models address limitations of traditional methods, offering improved efficiency and accuracy.
• Further development and application of these models can accelerate safe drug discovery.